Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Larry Salberg

Neurology with Special Qualifications in Child Neurology Merrillville, IN Medical Doctor

NPI 1073666749 CMS profile 139068

521 E 86Th Ave, Suite Z, Merrillville, IN 46410

Open in the dashboard

General payments

$26,597

1,412 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Larry Salberg of Merrillville, IN is reported in the CMS Open Payments database as having received $26,597 across 1,412 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,765 244
2024 General $5,015 246
2023 General $4,291 220
2022 General $4,092 212
2021 General $3,779 194
2020 General $2,697 170
2019 General $1,958 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Larry Salberg
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Larry Salberg were reported at $4,765. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Larry Salberg Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $1,958 $262 $68–$1,313 $163
2020 $2,697 $188 $46–$1,222 $114
2021 $3,779 $183 $45–$1,356 $132
2022 $4,092 $229 $72–$1,177 $149
2023 $4,291 $269 $93–$1,195 $160
2024 $5,015 $300 $98–$1,428 $164
2025 $4,765 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $2,390 112 payments
  2. Jazz Pharmaceuticals Inc. $1,905 86 payments
  3. Teva Pharmaceuticals USA, Inc. $1,814 97 payments
  4. Novartis Pharmaceuticals Corporation $1,576 122 payments
  5. AbbVie, Inc. $1,353 108 payments
  6. Neurocrine Biosciences, Inc. $1,031 37 payments
  7. Alexion Pharmaceuticals, Inc. $768 32 payments
  8. Avadel CNS Pharmaceuticals, LLC $682 25 payments
  9. Lundbeck LLC $671 32 payments
  10. ACADIA Pharmaceuticals Inc $633 34 payments
  11. Other $13,772 727 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $26,335 1,395 payments
  2. Education $131 6 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $131 11 payments
Products named General payments · program years 2019–2025
  1. TYSABRI $1,468 71 payments
  2. XYWAV $1,135 51 payments
  3. KESIMPTA $836 77 payments
  4. INGREZZA $834 25 payments
  5. VUMERITY Neurology $748 33 payments
  6. VUMERITY Neurology $700 40 payments
  7. AJOVY $695 29 payments
  8. AIMOVIG $688 37 payments
  9. LUMRYZ $682 25 payments
  10. ZEPOSIA $640 29 payments
  11. Other $20,487 1,163 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

3,338

Median for Neurology: 833

Drug cost

$602,359

Median for Neurology: $202,670

Branded share of claims

31.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Epidiolex Cannabidiol (Cbd) Brand 17 $120,127
Nurtec Odt Rimegepant Sulfate Brand 39 $61,575
Rexulti Brexpiprazole Brand 23 $44,764
Horizant Gabapentin Enacarbil Brand 32 $37,214
Lamictal Lamotrigine Brand 26 $37,190
Qulipta Atogepant Brand 28 $35,633
Botox Onabotulinumtoxina Brand 24 $32,336
Fycompa Perampanel Brand 19 $30,388
Topamax Topiramate Brand 17 $23,261
Neupro Rotigotine Brand 16 $21,854

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$374,674

Of which drugs: $64,385

Medicare patients

632

Average age 71

Services billed

15,732

322 women, 310 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Depression 37%
Diabetes 34%
Ischemic heart disease 29%
Chronic kidney disease 23%
COPD 20%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 26 10,200 $50,823

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 55 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYWAV
$346 — —
LUMRYZ
$327 — —
KESIMPTA
$288 — —
Epidiolex
$239 17 —
ZEPOSIA
$221 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 55 with Patron

Records

1,412 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record